Related Experiment Video
Updated: Apr 23, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Faecal microbiota transplantation: from practice to legislation before considering industrialization
1URMITE, UM63, CNRS 7278, IRD 198, INSERM 1095, Aix Marseille Université, Marseille, France; Assistance Publique Hôpitaux de Marseille, CHU Nord, Pôle Infectieux, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
Faecal microbiota transplantation (FMT) offers a more effective treatment for recurrent Clostridium difficile infections than antibiotics. Ongoing research explores standardized protocols and novel delivery methods like pills for wider adoption.
Area of Science:
- Gastroenterology
- Microbiology
- Infectious Diseases
Background:
- Recurrent Clostridium difficile infections (rCDI) present a significant medical challenge.
- Faecal microbiota transplantation (FMT) has emerged as a highly effective treatment for rCDI, surpassing traditional antibiotic therapies.
- Despite its efficacy, FMT faces challenges related to heterogeneous protocols and regulatory oversight.
Purpose of the Study:
- To review the current landscape of faecal microbiota transplantation for recurrent Clostridium difficile infections.
- To discuss the challenges and advancements in donor selection, transplantation methodology, and regulatory considerations.
- To highlight emerging trends such as frozen microbiota, synthetic microbiota, and oral FMT formulations.
Main Methods:
- Review of existing literature on faecal microbiota transplantation for Clostridium difficile infections.
- Analysis of regulatory guidelines from agencies like the FDA and French authorities.
- Discussion of various FMT methodologies, including donor screening, administration routes, and novel formulations.
Main Results:
- FMT demonstrates superior efficacy compared to antibiotics for rCDI, with minimal serious side effects.
- Standardization of donor screening and transplantation protocols remains a challenge.
- Frozen microbiota and nasogastric administration are effective, while synthetic microbiota lacks robust evidence.
- Oral FMT formulations (pills) are under investigation and show promise for widespread use.
Conclusions:
- Faecal microbiota transplantation is a well-established and effective treatment for recurrent Clostridium difficile infections.
- Standardization of protocols, regulatory clarity, and development of novel delivery systems are crucial for broader clinical application.
- Emerging technologies like oral FMT hold significant potential for industrialization and increased patient accessibility.
Related Concept Videos
Development of Human Microbiota
Introduction to the Human Microbiota
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Microbiota of the Large Intestine
Microbes in the Production of Fermented Foods
Bacterial Flora of the Large Intestine
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.

